Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Article Oncology

Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

Stephen Liu et al.

Summary: IMpower133 trial showed that adding atezolizumab to CP/ET for first-line treatment of ES-SCLC significantly improved patients' overall survival. Atezolizumab demonstrated potential efficacy in treating ES-SCLC.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman et al.

Summary: The study showed that first-line treatment with durvalumab plus platinum-etoposide resulted in sustained improvement in overall survival, while the addition of tremelimumab to this combination did not significantly enhance efficacy. These findings support the use of durvalumab plus platinum-etoposide as a new standard of care for extensive-stage small-cell lung cancer.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331

D. R. Spigel et al.

Summary: Nivolumab did not show survival benefit compared to chemotherapy in relapsed SCLC, but there is a potential survival benefit in certain baseline characteristics.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial

Yun Fan et al.

Summary: The study demonstrated potential antitumor activity of camrelizumab plus apatinib in patients with ED-SCLC who had failed platinum-based chemotherapy, including those who were chemotherapy-sensitive and chemotherapy-resistant. Treatment-related adverse events of grade 3 or higher were reported in a significant proportion of patients, leading to treatment discontinuation in some cases. Further clinical studies are warranted to explore the efficacy of this combination therapy in SCLC.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Review Oncology

Considerations for treatment duration in responders to immune checkpoint inhibitors

Thomas U. Marron et al.

Summary: Although immune checkpoint inhibitors (ICIs) have improved overall survival for cancer patients, the optimal duration of therapy remains undefined and further research is needed. Early trials have shown that a significant percentage of patients have durable responses to ICIs, prompting the question of whether patients may be receiving too much treatment and if durable remissions can still be achieved with shorter courses. Designing well-controlled trials to identify biomarkers for predicting patients who would benefit from shorter courses of immunotherapy is crucial for future work in this area.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Oncology

Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study

Ying Cheng et al.

Summary: The study evaluated the efficacy and safety of anlotinib as a third-line and subsequent treatment for Chinese patients with SCLC. Anlotinib showed improved progression-free survival (PFS) and overall survival (OS) compared to placebo, with a favourable safety profile.

BRITISH JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

SHR-1316, an anti-PD-L1 antibody, plus chemotherapy as the first-line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study

Lan Mu et al.

Summary: The study demonstrates that SHR-1316 plus liposomal irinotecan and 5-fluorouracil shows promising efficacy and manageable safety profile as a first-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC). The median progression-free survival (PFS) was 8.5 months, with an objective response rate (ORR) of 52.2% and disease control rate (DCR) of 73.9%.

THORACIC CANCER (2021)

Add to Collection

Article Oncology

Survival and pretreatment prognostic factors for extensive-stage small cell lung cancer: A comprehensive analysis of 358 patients

Li-Ling Huang et al.

Summary: This study retrospectively collected detailed medical records of 358 patients with ES-SCLC from January 1, 2011 to December 31, 2018 in a top-level cancer hospital in China. It identified age ≥70, smoking index ≥400, bone multimetastasis, two tumor biomarkers (cyfra211, CA125), and two laboratory indexes (decreased Na, PLR <76) as independent prognostic factors for OS in this patient population, providing real-world evidence for survival and prognosis.

THORACIC CANCER (2021)

Add to Collection

Article Oncology